WO2006022243A1 - Corl1遺伝子を標的とした脊髄神経細胞の種類を識別する方法 - Google Patents
Corl1遺伝子を標的とした脊髄神経細胞の種類を識別する方法 Download PDFInfo
- Publication number
- WO2006022243A1 WO2006022243A1 PCT/JP2005/015245 JP2005015245W WO2006022243A1 WO 2006022243 A1 WO2006022243 A1 WO 2006022243A1 JP 2005015245 W JP2005015245 W JP 2005015245W WO 2006022243 A1 WO2006022243 A1 WO 2006022243A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- gene
- spinal nerve
- corll
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to a gene Corll that is specifically expressed in spinal cord interneuron-euron dI4, dI5, dILA, and dILB, and to the use of the gene for identifying the type of spinal nerve cell
- the spinal nervous system is a central nervous system that plays a very important role in the control of movement and perception.
- Regenerative therapies are being investigated as treatments for spinal nerve disorders such as spinal cord injury.
- spinal nerve disorders such as spinal cord injury.
- it has been considered to transplant spinal nerve cells that have been induced by force in vitro, such as ES cells, or to promote regeneration in vivo from the neural stem cells of patients themselves.
- Non-patent Document 1 A method for inducing differentiation of spinal motor neurons from ES cells with high efficiency has been developed (Non-patent Document 1).
- spinal motor neuron progenitor cells can be purified by using ES cells in which GFP is knocked in at the HB9 gene locus specific to motor neuron cells!
- the developmental mechanism of the fetal period has also been elucidated for spinal neurons other than motor neurons (Non-patent Documents 2-5).
- Non-patent Documents 2-5 there are about 15 different types of nerve cells in the spinal cord (Non-patent Documents 2-5).
- spinal nerve cells various homebox transcription factors that are selectively expressed have been identified, and individual spinal nerve cells can be identified by combining these expressions.
- a marker that is specifically expressed has not yet been identified, and although it is possible to identify the place of development in the fetal period of development, in vitro It is difficult to identify some spinal nerve cell populations in the mixed spinal nerve cell populations that were induced to differentiate in, the spinal nerve cell populations that migrated in vivo after development, and the adult regenerated spinal nerve cell populations. is there.
- Non-patent document 1 Wichterle H, Lieberam I, Porter AP and Jessell TM. Directed differen tiation of embryonic stem cells into moter neurons. Cell 2002 Aug; 110: 385— 397
- Non-patent document 2 Jessell TM. Neuronal specification in the spinal Nat Rev Genetics 2000 Oct; l (l): 20— 29. (Review)
- Non-Patent Document 3 Caspary T, Anderson KV. Patterning cell types in the dorsal spinal cord: what the cord: Inductive signal s and transcriptional codes. mouse mutants say. Nat Rev Neurosci. 2003 Apr; 4 (4): 289-97.
- Non-Patent Literature 4 Muller T, Brohmann H, Pierani A, Heppenstall PA, Lewin GR, Jessell TM, Birchmeier C.
- the homeodomain factor lbxl distinguishes two major programs of neuronal differentiation in the dorsal spinal cord. Neuron. 2002 May 16; 34 (4): 551 -62.
- Non-Patent Document 5 Gross MK, Dottori M, Goulding M. Lbxl specifies somatosensory ass ociation interneurons in the dorsal spinal cord. Neuron. 2002 May 16; 34 (4): 535- 49. Disclosure of the Invention
- the present invention has been made in view of such circumstances, and an object thereof is to provide a method and a reagent for identifying the type of spinal nerve cells. More specifically, the present invention uses a method for identifying spinal nerve cells dll, dI2, dI3, dI4, dI5, dI6, dILA or dILB using the expression of endogenous CorlKCorepressor for Lbxl) as an index, and It is an object of the present invention to provide a reagent for detecting the expression of endogenous Corll gene in the method.
- the present inventors selectively express in the mouse fetal brain region. Genes were searched by the subtraction method. As a result, a cDNA fragment encoding Corll was obtained. When the expression of Corll was examined by RT-PCR, in situ hybridization, and immunostaining using polyclonal antibodies, Corll was particularly selectively and strongly expressed in the central nervous system during fetal period. Next, the expression of Corll in the fetal spinal cord was examined in detail. Expression—Comparison with various markers to identify the type of euron revealed that Corll is specifically expressed in spinal cord-exon dI4, dI5, dILA and dILB.
- a reagent for identifying the types of spinal nerve cells which contains, as an active ingredient, a polynucleotide that hybridizes to a transcript of the Corll gene.
- a polynucleotide that is hybridized under stringent conditions to a polynucleotide comprising at least one nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 5 A reagent for identifying the types of spinal nerve cells, containing as an active ingredient.
- a reagent for identifying the type of spinal nerve cell comprising as an active ingredient an antibody that binds to the translation product of the Corll gene.
- SEQ ID NO: 2 SEQ ID NO: 4, SEQ ID NO: 6
- an antibody that binds to an amino acid sequence described in at least one selected from the group consisting of or a polypeptide having a partial sequence ability is selected.
- a polynucleotide that hybridizes to the transcript of the Corll gene and Brn3a, Pax2, L a type of spinal nerve cell including a combination with a polynucleotide that hybridizes to a transcript of one or more genes selected from the group consisting of bxl, Liml, Lim2, LH2A, LH2B, Isll, Lmxlb, Tlxl and Tlx3 Kit for identification.
- a kit for identifying the type of spinal nerve cell, comprising an polynucleotide to be hybridized as an active ingredient.
- kits according to any one of [6] to [9], wherein the spinal nerve cells to be identified are dll, dI2, dI3, dI4, dI5, dI6, dILA, or dIL B.
- a method for identifying the type of spinal nerve cell comprising a step of detecting a transcription product or translation product of a Corll gene in the spinal cord nerve cell.
- a method for identifying types of spinal nerve cells (1) a polynucleotide that hybridizes under stringent conditions to a polynucleotide comprising at least one base sequence described in SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 5;
- An antibody that binds to a polypeptide having at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6 or a partial sequence ability thereof, to spinal nerve cells A method comprising the step of contacting.
- a step of discriminating at least one spinal nerve cell selected from the group force consisting of dll, dI2, dI3 and dI6 and at least one spinal nerve cell selected from the group force consisting of dI4, dI5, dILA and dILB The method according to [14] or [15], comprising:
- the present invention also provides:
- FIG. 1 is a diagram schematically showing the structure and homology of Corll.
- FIG. 2 is a photograph showing the expression of Corll in adult mouse silkworm tissue and the expression in the hindbrain and spinal cord of E12.5 mice.
- FIG. 3 is a photograph showing a comparison of the expression of Corll, Pax7 and j8 ⁇ -tubulin in the E13.25 spinal cord.
- FIG. 4 is a photograph showing a comparison of the expression of Corll, Brn3a, Liml and Isll in the E10.75 spinal cord of Corll.
- FIG. 5 is a photograph showing comparison of the expression of Corll, Brn3a, and Liml in the E13.25 spinal cord of Corll.
- FIG. 6 is a diagram schematically showing the expression pattern of Corll in the nascent spinal cord.
- TFs means transcriptional regulators.
- FIG. 7 is a photograph showing the expression of Corll in spinal nerve cells induced to differentiate in vitro from ES cells.
- FIG. 8 is a photograph showing the expression of Corll in spinal nerve cells induced in vitro from ES cells.
- the present invention provides a reagent for identifying the type of spinal nerve cell, which contains, as an effective component, a polynucleotide that is hybridized to the transcript of the Corll gene.
- the chain length of the polynucleotide of the present invention is not particularly limited, and so-called “oligonucleotides” are also included in the polynucleotide of the present invention.
- spinal neurons of the Corll gene force by the present inventors is substantially expressed in dI4, dI5, dILA, and dl LB, but not substantially expressed in dll, dI2, dI3, and dI6 Indicated. Therefore, typical examples of spinal nerve cells that are subject to cell type identification by the reagent of the present invention include dll, dI2, dI3, dI4, dI5, dI6, dILA, or dILB.
- identifying the type of spinal cord nerve cell refers not only to identifying that the target spinal cord nerve cell is a specific type of spinal cord nerve cell, but also to the spinal cord to be targeted. This includes the case where neuronal cells are identified as sputum in certain types of spinal neurons. For example, if a Corll gene is substantially expressed in a target spinal cord neuron, the spinal cord neuron can be identified as “possibly dI4, dI5, dILA or dILB”. It can also be identified as “not dll, dI2, dI3, and dI6”.
- the spinal cord neuron if the target spinal cord neuron does not substantially express the Corll gene, the spinal cord neuron is identified as “possibly dll, dI2, dI3, or dI6”. It can also be identified as “not dI4, dI5, dIL A and dILB”.
- the "Corll gene” that serves as an index for identifying the type of spinal nerve cells is not particularly limited as long as it exhibits the expression specificity in the above spinal nerve cells. Vertebrate Corll genes can be used in the present invention.
- the mouse Corll gene is known, and its nucleotide sequence is shown in SEQ ID NO: 1, and the amino acid sequence is shown in SEQ ID NO: 2.
- the Corll gene of the present invention includes a homologue thereof, for example, human Corll (nucleotide sequence SEQ ID NO: 3 includes the amino acid sequence shown in SEQ ID NO: 4) and rat Corll (base sequence shown in SEQ ID NO: 5 and amino acid sequence shown in SEQ ID NO: 6).
- a naturally occurring mutant such as an allelic mutant exists in the Corll gene, and such a mutant is also an index for identifying the type of spinal nerve cell in the present invention. sell.
- the "Corll gene" used in the present invention can be defined as the endogenous DNA selected from (1) to (4) below.
- the amino acid level is within 10 amino acids (eg, within 5 amino acids, within 3 amino acids) as compared with the nucleotide sequence of the Corll gene described in any one of 1, 3, and 5.
- vertebrate DNA corresponding to a specific vertebrate DNA generally has high homology with the DNA of the specific vertebrate.
- High homology means 50% or more, preferably 70% or more, more preferably 80% or more, more preferably 90% or more (e.g., 95% or more, or 96%, 97%, 98% or 99% or higher) homology. This homology is determined by the mBL AST algorithm (Altschul et al. (1990) Proc. Natl. Acad. Sci. USA 87: 2264—8; Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90: 5873 -It can be determined by 7).
- vertebrate DNA corresponding to a specific vertebrate DNA is considered to hybridize under stringent conditions with a specific vertebrate DNA when in vivo forces are also isolated.
- stringent conditions for example, “2 X SSC, 0.1% SDS 50 .C”, “2 X SSC, 0.1% SDS 42 .C”, “1 X SSC 0.1% SDS 37 ⁇ ° C '', and more stringent conditions are ⁇ 2 X SSC, 0.1% SDS, 65 ° C '', ⁇ 0.5 X SSC, 0.1% SDS, 42 ° C '' and ⁇ 0.2 X SSC, 0.1% SDS, 65
- the condition of “C” can be mentioned.
- the polynucleotide that is the active ingredient of the reagent of the present invention hybridizes to the transcription product of the endogenous Corll gene.
- hybridization conditions for example, “2 X SSC, 0.1% SDS, 50 ° C.”, “2 XS SC, 0.1% SDS, 42 ° C '', ⁇ 1 X SSC, 0.1% SDS, 37 ° C '', and more stringent conditions such as ⁇ 2 X SSC, 0.1% SDS, 65 ° C '', ⁇ 0.5 X SSC, Examples include conditions such as “0.1% SDS, 42 ° C.” and “0.2 X SSC, 0.1% SDS, 65 ° C.”.
- probe is added for 1 hour or more at 68 ° C. And then allowed to form, and then washed 3 times for 20 minutes at room temperature in 2 X SSC, 0.1% SDS, followed by 20 minutes at 37 ° C in 1 X SSC, 0.1% SDS. This can be done 3 times, and finally it can be washed twice in 1 X SSC, 0.1% SDS at 50 ° C for 20 minutes.
- Prehybridization Solution CLO NTECH
- prehybridization at 55 ° C for 30 minutes or more, add labeling probe, and incubate at 37-55 ° C for 1 hour or more.
- it can be washed 3 times for 20 minutes at room temperature in 2 X SSC, 0.1% SDS, and once for 20 minutes at 37 ° C in 1 X SSC, 0.1% SDS.
- the temperature at the time of pre-hybridization, hybridization, or the second washing to be higher, more stringent conditions can be obtained.
- the temperature of the prehybridization and the hybridization can be 60 ° C
- the stringent condition can be 68 ° C.
- Those skilled in the art can set conditions by considering other conditions such as probe concentration, probe length, probe base sequence composition, reaction time, etc. in addition to conditions such as buffer salt concentration and temperature. can do.
- SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 5 group strength, which is a stringent condition with respect to the polynucleotide having at least one selected base sequence power
- the present invention relates to a reagent for identifying the type of spinal nerve cell, which contains a polynucleotide that is noblyzed below as an active ingredient.
- the polynucleotide in the reagent of the present invention is not particularly limited in its chain length as long as the expression of the Corll gene can be specifically detected, but is generally complementary to the base sequence of the Corll gene. It is a polynucleotide comprising a base sequence comprising at least 15 consecutive bases. Such a polynucleotide having a nucleotide sequence including at least 15 consecutive bases can be a probe for detecting the expression of Corll mRNA, or a primer for amplifying and detecting Corll mRNA. Normally 15 to 10 when used as a probe It is desirable that the polynucleotide is composed of 0, preferably 15 to 35 bases. Further, when used as a primer, a polynucleotide composed of at least 15 bases, preferably about 30 before and after, is desirable.
- the polynucleotide When used as a probe, the polynucleotide is appropriately labeled with a radioisotope or a non-radioactive compound.
- the 3 'end region of the polynucleotide When used as a primer, the 3 'end region of the polynucleotide is complementary to the target sequence, and a restriction enzyme recognition sequence, tag, etc. are added to the 5' end side. Can be designed.
- Such a polynucleotide having at least 15 consecutive base sequences can be hybridized to the CorRNA.
- Polynucleotides include non-natural bases such as 4-acetylcytidine, 5- (carboxyhydroxymethyl) uridine, 2, -0-methylcytidine, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxyl.
- the polynucleotide that is the active ingredient of the reagent of the present invention is based on the known sequence information of Corll. Therefore, it can also be produced by chemical synthesis. In addition, it can be prepared from cells that express the Corll gene using a hybridization method, a PCR method, or the like.
- the Corll gene can be used in combination with other known markers, whereby the spinal nerve cell type is identified in more detail. It becomes possible. Therefore, the present invention relates to a polynucleotide that hybridizes to the transcription product of the Corll gene, Brn3a, Pax2, Lbxl, Liml, Lim2, LH2A, LH2B, Isll, Lmxlb, Tlxl (Nat Rev Neurosci. 2003 Apr; 4 ( 4): 289- 97 Caspary T, Anderson KV. Patterning cell types in the dorsal spinal cord: what the mouse mutan ts say.) And Tk3 (Nat Rev Neurosci.
- kits for identifying spinal cord neuron types comprising a combination with a polynucleotide that hybridizes to a transcript of one or more genes selected from the group of others.
- the polynucleotide is stringent with respect to the polynucleotide having the nucleotide sequence ability described in at least one selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3 and SEQ ID NO: 5.
- the present invention relates to a kit for discriminating the types of spinal nerve cells, which contains a polynucleotide that can be noisy under various conditions as an active ingredient.
- the nucleotide sequence of mouse Brn3a is SEQ ID NO: 7, the amino acid sequence is SEQ ID NO: 8, the nucleotide sequence of human Brn3a is SEQ ID NO: 9, the amino acid sequence is SEQ ID NO: 10, and the nucleotide sequence of rat Brn3a is sequenced.
- the amino acid sequence is shown in SEQ ID NO: 12.
- the Brn3a gene can be defined as an endogenous DNA that also selects the following (1) to (4) forces, as in the case of the Corll gene described above.
- DNA encoding a protein having the amino acid sequence of SEQ ID NO: 8, 10, or 12 (2) DNA comprising the base sequence described in any one of SEQ ID NOS: 7, 9, and 11,
- the base sequence of mouse Pax2 is shown in SEQ ID NO: 13, the amino acid sequence is shown in SEQ ID NO: 14, the base sequence of human Pax2 is shown in SEQ ID NO: 15, and the amino acid sequence is shown in SEQ ID NO: 16.
- the Pax2 gene can be defined as endogenous DNA that is selected from the following (1) to (4) forces.
- the base sequence of mouse Lbxl is shown in SEQ ID NO: 17, the amino acid sequence is shown in SEQ ID NO: 18, the base sequence of human Lbxl is shown in SEQ ID NO: 19, and the amino acid sequence is shown in SEQ ID NO: 20.
- the Lbxl gene can be defined as the endogenous DNA selected from the following (1) to (4).
- the base sequence of mouse Liml is shown in SEQ ID NO: 21, the amino acid sequence is shown in SEQ ID NO: 22, the base sequence of human Liml is shown in SEQ ID NO: 23, and the amino acid sequence is shown in SEQ ID NO: 24.
- the Liml gene can be defined as endogenous DNA that is selected from the following (1) to (4).
- the base sequence of mouse Lim2 is SEQ ID NO: 25, the amino acid sequence is SEQ ID NO: 26, the base sequence of human Lim2 is SEQ ID NO: 27, the amino acid sequence is SEQ ID NO: 28, and the base sequence of rat Lim2 is sequenced.
- the amino acid sequence is shown in SEQ ID NO: 30.
- the Lim2 gene can be defined as an endogenous DNA selected from the following (1) to (4) forces.
- DNA of another vertebrate corresponding to the DNA comprising the nucleotide sequence set forth in any one of SEQ ID NOs: 25, 27 and 29.
- the mouse Isll base sequence is SEQ ID NO: 31, the amino acid sequence is SEQ ID NO: 32, the human Isll base sequence is SEQ ID NO: 33, the amino acid sequence is SEQ ID NO: 34, and the Hsll base sequence is Arrangement Column number: 35, the amino acid sequence is shown in SEQ ID NO: 36.
- the Isll gene can be defined as endogenous DNA that is selected from the following (1) to (4) forces.
- LH2A gene can be defined as endogenous DNA for which the following (1) to (4) forces are also selected.
- the base sequence of mouse LH2B is SEQ ID NO: 41, the amino acid sequence is SEQ ID NO: 42, the base sequence of human LH2B is SEQ ID NO: 43, the amino acid sequence is SEQ ID NO: 44, and the base sequence of rat LH2B is SEQ ID NO: 45, amino acid sequence is shown in SEQ ID NO: 46.
- the LH2B gene can be defined as endogenous DNA that is selected from the following (1) to (4) forces.
- Another vertebrate DNA corresponding to the DNA consisting of the nucleotide sequence set forth in any one of SEQ ID NOs: 41, 43, and 45.
- the base sequence of mouse Lmxlb is SEQ ID NO: 47
- the amino acid sequence is SEQ ID NO: 48
- the base sequence of human Lmx lb is SEQ ID NO: 49
- the amino acid sequence is SEQ ID NO: 50
- the base sequence of rat Lmxlb is SEQ ID NO: 51
- amino acid sequence is shown in SEQ ID NO: 52.
- the Lmxlb gene can be defined as an endogenous DNA selected from the following (1) to (4) forces.
- SEQ ID NO: 47, 49 DNA comprising the nucleotide sequence according to any one of 51,
- Tlx 1 gene can be defined as the endogenous DNA that is selected from (1) to (4) below.
- Tlx3 The base sequence of mouse Tlx3 is shown in SEQ ID NO: 57, the amino acid sequence is shown in SEQ ID NO: 58, the base sequence of human Tlx3 is shown in SEQ ID NO: 59, and the amino acid sequence is shown in SEQ ID NO: 60.
- the Tlx 3 gene can be defined as the endogenous DNA selected from the following (1) to (4) force
- the kit of the present invention may appropriately contain reagents for detecting the expression of transcripts of Corll and other marker genes, buffers and the like. You can also package instructions that describe how to use the kit.
- the present invention also provides a reagent for identifying the type of spinal nerve cell, which contains an antibody that binds to the translation product of the Corll gene as an active ingredient. Furthermore, in a preferred embodiment of the present invention, the amino acid sequence according to at least one selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6 is used. The present invention relates to a reagent for identifying the type of spinal nerve cell, which contains a binding antibody as an active ingredient.
- Antibodies that are active ingredients of the reagent of the present invention include polyclonal antibodies, monoclonal antibodies, chimeric antibodies, single chain antibodies (scFv) (Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85: 5879-83; The Pharmacology of Monoclonal Antibody, Vol. 113, Rosenburg and Moore ed., Springer Verlag (1994) pp. 269-315), humanized antibody, multispecific antibody (LeDous Sal et al. (1992) Int. J. Cancer Suppl. 7: 58-62; Paulus (1985) Behring Inst. Mitt.
- the body may be modified with PEG or the like as necessary. It can also be produced as a fusion protein with ⁇ -galatatosidase, maltose binding protein, GST, green fluorescent protein (GFP), etc., so that it can be detected without using a secondary antibody. It can also be modified so that the antibody can be detected and recovered using avidin, streptavidin, or the like by labeling the antibody with piotin or the like.
- Polyclonal antibodies can be obtained, for example, from serum collected from an immunized animal by immunizing a mammal with a purified Corll polypeptide or a fragment thereof together with an adjuvant as necessary.
- Mammals used here are not particularly limited, but rodents, rabbits, and primates are common. Examples include rodents such as mice, rats, and hamsters, maggots such as magpies, and primates such as monkeys such as power-quiskeys, monkeys, baboons, and chimpanzees.
- the sensitizing antigen is appropriately diluted and suspended in Phosphate-Buffered Saline (PBS) or physiological saline, etc., mixed with an adjuvant as necessary, emulsified, and then intraperitoneally or subcutaneously. It is done by injection. Thereafter, a sensitizing antigen preferably mixed with Freund's incomplete adjuvant is administered several times every 4 to 21 days. Antibody production can be confirmed by measuring the desired antibody level in serum by a conventional method. Finally, the serum itself may be used as a polyclonal antibody or may be further purified. As a specific method, for example, “Current Protocols in Molecular Biology” (John Wiley & Sons (1987) Section 11.12-11.13) can be referred to.
- the spleen is removed from the animal immunized as described above, immune cells are separated from the spleen, and appropriate myeloma cells and polyethylene glycol (PEG) are isolated. ) Etc. to create a no, an hybridoma.
- Cell fusion can be carried out according to Milstein's method (Galfre and Milstein (1981) Methods Enzymol. 73: 3-46).
- myeloma cells especially fusion cells can be selected by drugs Prefer cell to do.
- HAT culture medium a culture medium containing hypoxanthine, aminobreterin, and thymidine that die other than the fused cells.
- a clone that produces an antibody that binds to the Corll polypeptide or a fragment thereof is selected from the generated hybridoma.
- the selected clone is transplanted into the abdominal cavity of a mouse or the like, and ascites is collected to obtain a monoclonal antibody.
- “Current Protocols in Molecular Biology Joohn Wiley & Sons (1987) Section 11.4—11.11) can also be referred to.
- Ibridoma sensitized human lymphocytes initially infected with EB virus with an immunogen in vitro, and fused the sensitized lymphocytes with human-derived myeloma cells (such as U266). It can also be obtained by a method for obtaining a hyperidoma that produces human antibodies (Japanese Patent Laid-Open No. 63-17688). Human antibodies can also be obtained using antibody-producing cells produced by sensitizing a transgenic animal having a repertoire of human antibody genes (WO92 / 0391 8; WO93 / 02227; WO94 / 02602; W094). WO25 / 34096; Mendez et al. (1997) Nat. Genet. 15: 146-56 etc.). An example of using no hyperidoma is a method in which an oncogene is introduced into immune cells such as antibody-producing lymphocytes and immortalized.
- Antibodies can also be produced by gene recombination technology (Borrebaeck and Larrick).
- the gene encoding the antibody is cloned into a hyperidoma or antibody-producing cell (such as sensitized lymphocyte).
- the obtained gene is incorporated into an appropriate vector, the vector is introduced into a host, and the host is cultured to produce antibodies.
- a recombinant antibody is also included in the active ingredient of the reagent of the present invention.
- Typical recombinant antibodies include chimeric antibodies composed of non-human antibody-derived variable regions and human antibody-derived constant regions, non-human antibody-derived complementarity determining regions (CDRs), and human antibody-derived frame regions ( (FR) and constant region and potent human ivy antibody (Jones et al. (1986) Nature 321: 522-5; Reichmann et al. (1988) Nature 332: 323-9; Presta (1992) Curr. O p. Struct. Biol. 2: 593-6; Methods Enzymol. 203: 99-121 (1991)).
- CDRs non-human antibody-derived complementarity determining regions
- FR human antibody-derived frame regions
- the antibody fragment is the above-described polyclonal or monoclonal antibody, papain, pepsin. It can manufacture by processing with enzymes, such as. Alternatively, it can be produced by genetic engineering using a gene encoding an antibody fragment (Co et al. (1994) J. Im ⁇ nol. 152: 2968-76; Better and Horwitz (1989) Methods Enzymol 178: 476-96; Pluc kthun and Skerra (1989) Methods Enzymol. 178: 497-515; Lamoyi (1986) Methods Enzymol. 121: 652-63; Rousseaux et al. (1986) 121: 663-9; Bird and Walker (1991) Trends Biotechnol. 9: 132-7).
- Multispecific antibodies include bispecific antibodies (BsAb), diabodies (Db), and the like.
- Multi-characteristic antibodies consist of (1) a method of chemically coupling antibodies of different specificities with a heterobifunctional linker (Paulus (1985) Bohring Inst. Mill. 78: 118-32), (2) different monoclonals. Methods for fusing hybridomas that secrete antibodies (Millstein and Cuello (1983) Nature 3 05: 537-9), (3) Mouse myeloma cells using different monoclonal antibody light and heavy chain genes (4 types of DNA), etc. After transfecting the eukaryotic cell expression system of the gene and isolating the bispecific monovalent moiety (Zimmeremann (1986) Rev. Physio. Biochem.
- Db is a dimeric antibody fragment composed of two divalent polypeptide chains constructed by gene fusion, and can be prepared by a known method (Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-8; EP404097; W093 / 11161).
- Recovery and purification of antibodies and antibody fragments can be performed using proteins A and G.
- it can be purified by the above-described protein purification technique in the same manner as polypeptides other than antibodies (Antibodies: A Laboratory Manual, Ed. Harlow and David Lane, Cold Spring Harbor Laboratory (1988)).
- protein A is used for purification of the antibody of the present invention
- a protein A column such as Hyper D, POROS, or Sepharose F.F. (Pharmacia) is known and can be used.
- the concentration of the obtained antibody can be determined by measuring its absorbance or by enzyme-linked immunosorbent assay (ELISA) or the like.
- the antigen-binding activity of the antibody can be measured by absorbance measurement, fluorescent antibody method, enzyme immunoassay (EIA), radioimmunoassay (RIA), ELISA, or the like. Measure by ELISA
- the Corll polypeptide or a fragment thereof is immobilized on a carrier such as a plate, and then a sample containing the target antibody is added.
- a sample containing an antibody a culture supernatant of antibody-producing cells, a purified antibody, and the like can be considered.
- a secondary antibody that recognizes an antibody that is an active ingredient of the reagent of the present invention is added, and the plate is incubated.
- the plate is then washed and the label attached to the secondary antibody is detected. That is, when the secondary antibody is labeled with, for example, alkaline phosphatase, the antigen binding activity can be measured by adding an enzyme substrate such as trope-phosphate and measuring the absorbance.
- an enzyme substrate such as trope-phosphate
- a commercially available system such as BIAcore (Pharmacia) can also be used for antibody activity evaluation.
- kits for identifying spinal cord neuron types comprising a combination with an antibody that binds to the translation product of.
- a group consisting of SEQ ID NO: 2, SEQ ID NO: 4 and SEQ ID NO: 6 is selected from the group consisting of at least one amino acid sequence or a partial sequence thereof.
- the present invention relates to a kit for identifying types of spinal nerve cells, which is contained as an active ingredient.
- the kit of the present invention may appropriately contain a reagent for detecting the binding activity, a buffer solution and the like. You can also package instructions that describe how to use the kit.
- the present invention also provides a method for discriminating the types of spinal nerve cells, comprising the step of detecting a transcription product or translation product of a Corll gene in the spinal cord nerve cells.
- the detection of the transcript of the Corll gene in the method of the present invention is performed by the above-described method of the present invention. It can be carried out by contacting a nucleotide with a nucleic acid extract derived from a cell sample considered to contain spinal cord intercalation-euron, and detecting the nucleic acid that hybridizes with the polynucleotide in the nucleic acid extract. .
- the polynucleotide probe is preferably labeled with a radioisotope or non-radioactive compound.
- radioisotopes for labeling include 35 S, 3 H, and the like.
- RNA binding to the marker can be detected by detecting silver particles by emulsion autoradiography.
- piotin, digoxigenin and the like are known as a conventional non-radioactive isotope for labeling a polynucleotide probe.
- the detection of the marker for labeling of piotin can be carried out using, for example, fluorescence or avidin labeled with an enzyme such as alkaline phosphatase or horse radish peroxidase.
- an enzyme labeled with an enzyme such as fluorescence or alkaline phosphatase or horse radish peroxidase can be used.
- enzyme labels incubate with enzyme substrate and detect by depositing a stable dye at the marker location.
- the transcript of the Corll gene is hybridized with the polynucleotide primer by a technique such as RT-PCR. It can be detected by amplifying the nucleic acid.
- the detection of the translation product of the Corll gene in the method of the present invention comprises contacting the above-described antibody with a protein extract derived from a cell sample that is thought to contain spinal cord-interactive euron, and then detecting the protein binding to the antibody. It can be implemented by detecting.
- the antibody antigen-binding activity can be measured by absorbance measurement, fluorescent antibody method, enzyme immunoassay (EIA), radioimmunoassay (RIA), ELISA, or the like.
- a preferred embodiment for identifying spinal nerve cells of the present invention includes a method comprising the following steps.
- SEQ ID NO: 1 SEQ ID NO: 3 and SEQ ID NO: 5 Power of group strength Poly which hybridizes under stringent conditions to a polynucleotide comprising at least one selected base sequence Nucleotides,
- At least one spinal nerve cell selected from the group force consisting of dll, dI2, dI3 and dI6 and dI4, dI5, dILA and A method comprising the step of discriminating at least one spinal nerve cell from which a group force consisting of dILB is also selected can be mentioned.
- the preferred embodiment for identifying spinal cord neurons of the present invention is selected from the group consisting of Brn3a, Pax 2, Lbxl, Liml, Lim2, LH2A, LH2B, Isll, Lmxlb, Tkl, and Tlx3.
- Spinal neurons expressing transcripts of one or more genes and Brn3a, Pax2 Expresses transcripts of one or more genes selected from the group consisting of Lbxl, Liml, Lim2, LH2A, LH2B, Isll, Lmxlb, Tlxl, and Tlx3.
- the method including the process which can be mentioned.
- Corll shows specific expression in differentiation-induced spinal cord interstitial-euron
- it can be used in screening for spinal nerve cell differentiation-inducing reagents.
- the present invention provides a screening method for a candidate compound for a spinal nerve subdivision induction reagent using the expression of Corll as an index, comprising the following steps (a) to (c).
- cells capable of sorting into spinal nerve cells are preferably cell samples containing cells that can be induced to differentiate into spinal nerve cells, such as ES cells that are probably capable of spreading.
- In vitro differentiation of spinal cord neurons can be achieved by known ES cells, bone marrow stromal cells, and nerve-derived immortalized cell lines (Japanese Patent Publication No. 8-509215; Japanese National Publication No. 11-506930; Japanese National Publication No. 2) No. 002-522070), neuronal progenitor cells (Japanese Patent Publication No. 11-509729), and the like as a starting material.
- the test sample to be contacted with the cell may be any compound! /, But, for example, an expression product of a gene library, a synthetic low molecular compound library, a synthetic peptide library, an antibody, a bacterial release substance Cell (microbe, plant cell, animal cell) extract, cell (microbe, plant cell, animal cell) culture supernatant, purified or partially purified polypeptide, extract from marine organism, plant or animal, soil, random One phage peptide display library.
- the transcription product or translation product of the Corll gene can be detected using a polynucleotide that hybridizes to the transcription product of the Corll gene or an antibody that binds to the translation product of the Corll gene.
- Cell differentiation can be determined by comparison with the level of Corll expression in the absence of the test sample. That is, when the amount of the transcript or translation product of the Corll gene is increased compared to the case where it is detected in the absence of the test sample, the test sample is determined to have the ability to induce the differentiation of spinal cord neurons. it can.
- “increase” means, for example, 2 times, preferably 5 times, more preferably 10 times or more.
- test sample screened by this method can be a therapeutic drug candidate for a disease caused by any defect in spinal nerve cells as a spinal nerve cell differentiation-inducing reagent, and is considered useful.
- the present invention relates to the use of the following (a) or (b) in the manufacture of a reagent for identifying the types of spinal nerve cells.
- genes with different expression in the ventral and dorsal regions of the E12.5 mouse were identified by the subtraction (N-RDA) method.
- One of the isolated fragments was a cDNA fragment encoding a protein with unknown function.
- oligonucleotides were annealed and prepared to 100M.
- ad2A acggaatgatgt (SEQ ID NO: 62)
- ad3A accagagtctca (Tatsumi column number: 64)
- ad4S ctgatgggtgtcttctgtgagtgtgt (SEQ ID NO: 65)
- ad4A acacactcacag (eyes ti row number: 66)
- ad5S ccagcatcgagaatcagtgtgacagt (eye C row 3 ⁇ 4 ⁇ No .: 67)
- adl3A acgatcgacagt (SEQ ID NO: 70)
- RNA is prepared using RNeasy mini kit (Qiagen) and cDNA synthesis kit (TAKAR
- the cDNA amplified with ad2S was further amplified with 5 cycles of PCR. Amplification conditions were 94 ° C for 2 minutes, followed by 5 cycles of 94 ° C for 30 seconds, 65 ° C for 30 seconds, and 72 ° C for 2 minutes. And finally incubated at 72 ° C for 2 minutes. CDNA was purified and digested with Rsal using Qiaquick PCR purification kit (Qiagen). 3 g was used for each subtraction.
- the cDNA amplified with ad2S was further amplified with 5 cycles of PCR. Amplification was performed at 94 ° C for 2 minutes, followed by 5 cycles of 94 ° C for 30 seconds, 65 ° C for 30 seconds, and 72 ° C for 2 minutes, and finally 72 ° C for 2 minutes. did.
- CDNA was purified and digested with Rsal using Qiaquick PCR purification kit (Qiagen).
- Ad3 was added to 60 ng of Rsal-deleted cDNA.
- Tester and Driver prepared in 3 and 4 above were mixed, ethanol precipitated, and then dissolved in ⁇ CR buffer 1 ⁇ 1. After 5 minutes at 98 ° C., IxPCR buffer + lM NaCl 1 ⁇ 1 was added. After 98 minutes at 98 ° C, hybridization was performed at 68 ° C for 16 hours.
- Hybridized cDNA was amplified by ad3S as a primer with 10 cycles of PCR (incubated at 72 ° C for 5 minutes, then 94 ° C for 30 seconds, 65 ° C for 30 seconds, and 72 ° C for 2 minutes) The reaction was repeated 10 cycles), digested with Mung Bean Nuclease (TAKARA), and purified with Qiaquick PCR purification kit. Amplification was performed with 13 cycles of PCR. Amplification was performed at 94 ° C for 2 minutes, followed by 13 cycles of 94 ° C for 30 seconds, 65 ° C for 30 seconds, and 72 ° C for 2 minutes, and finally 72 ° C for 2 minutes. Incubated.
- Subtraction 1x 1 of 2xPCR buffer was added to 8ng of cDNA amplified in the first round. After 5 minutes at 98 ° C, IxPCR buffer + 1M NaCl 2 ⁇ 1 was added. After 5 minutes at 98 ° C, hybridization was performed at 68 ° C for 16 hours.
- the hybridized cDNA was digested with Rsal and purified with the Qiaquick PCR purification kit. This was amplified by 11 cycles of PCR using ad3S as a primer (incubated at 94 ° C for 2 minutes, then reacted at 94 ° C for 30 seconds, 65 ° C for 30 seconds, and 72 ° C for 2 minutes) Eleven cycles were performed, and finally it was incubated at 72 ° C for 2 minutes. Digestion with Rsal was performed and ad4 was added.
- A was cloned by RT-PCR.
- TAKARA Pyrobest polymerase
- Corll Fl GAGGTCGACATGGCATTGCTGTGTGGCCTTGGGAG (SEQ ID NO: 71)
- Corll Rl GAGGTCGACCTAGGGCAGCAGCGGAGGCTTGAAGG (SEQ ID NO: 72)
- the amplified cDNA was cloned into pCRII (Invitrogen), and the nucleotide sequence was analyzed using an ABI3100 sequence analyzer. As a result, it was confirmed that 936 amino acids were encoded, and this gene was named Corll.
- the protein was found to be highly homologous to SnoN and Dach (Fig. 1).
- a functionally unknown gene having high homology with Cor11 was found and named Corl2.
- a Drosophila gene (CG11093) with high homology to Corll was also found, suggesting that it has an evolutionarily conserved function.
- RNA PCR kit (TAKARA) and used in a cage type. PCR amplification was performed at 94 ° C for 2 minutes, followed by 35 cycles of 94 ° C for 30 seconds, 65 ° C for 30 seconds, and 72 ° C for 30 seconds, and finally at 72 ° C. Incubated for 2 minutes. PCR was performed with the following reaction solution composition.
- Corll F2 ATGCAGAGAGCATCGCTAAGCTCTAC (SEQ ID NO: 73)
- Corll R2 AAGCGGTTGGACTCTACGTCCACCTC (SEQ ID NO: 74)
- Corll is specifically expressed in the brain and testis in adults (Fig. 2). It was also revealed that brain expression is higher in the fetal period than in the adult. [0087] Next, expression analysis by in situ hybridization was performed using the Corll gene according to the following protocol.
- mice 12.5 day embryos were embedded in OCT, and fresh frozen sections with a thickness of 16 m were prepared. After drying on a slide glass, it was fixed with 4% PFA for 30 minutes at room temperature. After washing with PBS, hybridization (1 ⁇ g / ml DIGized RNA probe, 50% formamide, 5xSSC, 1% SDS, 50 ⁇ g / ml yeast RNA, 50 ⁇ g / ml Heparin) at 65 degrees For 40 hours. Thereafter, washing (50% formamide, 5 ⁇ SSC, 1% SDS) was performed at 65 ° C., and RNase treatment (5 ⁇ g / ml RNase) was performed at room temperature for 5 minutes.
- Corll As a result of expression analysis by in situ hybridization, in E12.5, Corll showed specific expression in the central nervous system and was selectively expressed in some cells of the hindbrain and spinal cord. (Fig. 2). Furthermore, as a result of analyzing the expression using a cross-section of the spinal cord, it was found that Corll is expressed exclusively in the dorsal region in the developing spinal cord. These results indicate that Corll is selectively expressed in some populations of the fetal central nervous system.
- a GST fusion protein expression vector was constructed with a region corresponding to amino acids 569-813 of Corll, an antigen required for immunization. After this vector was introduced into E. coli (JM109 strain), expression was induced by IPTG, and the fusion protein was recovered using dartathione beads. The rabbit was immunized several times with the fusion protein and then blood was collected, and the serum was also affinity purified with the GST-Collll antigen used for immunization to obtain an anti-Collll polyclonal antibody.
- Corll showed only MU expression but not co-expression with Pax7.
- all Corll positive cells expressed ⁇ -III tubulin, a progenitor cell marker committed to neurons.
- Corll is specifically expressed in some cells of the spinal cord, and it is considered that Corll is useful as a marker for identifying the type of nerve cell.
- Corll-expressing cells In the spinal cord on the dorsal side of the mouse, 6 types of interneurons from dll to (! 16 were produced in the early stage of development (E10-E11.5). E12-E13.5) are known to produce two types of intervening-eurons, dILA and dILB, from the same region. These neurons can be distinguished by their time of development and transcription factor markers that are selectively expressed in each. Therefore, the expression of Corll and various markers was compared in the early (E10.75) and late (E13.25).
- Example 31 Corll expression in spinal nerve cells induced in vitro differentiation from ES cells
- CCE cells an undifferentiated ES cell line, were added to Glasgow Minimum Essential Medium (Invitrogen), 10% Knockout serum replacement (Invitrogen), 2 mM L-glutmine (Invitrogen), O.lmM Non-essential amino acid (Invitrogen), ImM sodium pyruvate, sigma), 0. ImM 2—mercaptoethanol (sigma), lOOU / ml penicillin (Invitrogen), 100 ⁇ g / ml streptomycin (Invitrogen) Suspended at a rate of 1000 cells, seeded 10 1 on a plastic dish lid, and inverted and cultured for 2 days at 37 ° C, 5% carbon dioxide, 95% humidity.
- Glasgow Minimum Essential Medium Invitrogen
- 10% Knockout serum replacement Invitrogen
- 2 mM L-glutmine Invitrogen
- O.lmM Non-essential amino acid Invitrogen
- ImM sodium pyruvate sigma
- the formed cell mass (EB) was collected in the above medium, and 2 M retinoic acid (RA), sigma), 3; or 2 ⁇ M retinoic acid and 300 nM sonic hedg ehog (Shh) (R & D) And cultured for another 5 days.
- the gene Corll specifically expressed in spinal cord interneurons dI4, dI5, dILA and dILB has been identified.
- accurately identifying the type of nerve cells regenerated in the tissue or the type of nerve cells that have been induced to differentiate in vitro as a material to be transplanted is an important issue in terms of both safety and therapeutic efficacy. It becomes.
- Corll as a cell type identification marker is considered useful.
- the classification of dI4 and dI6 has been possible only by the location of the occurrence so far, that is, indistinguishable in neurons induced in an in vitro system that is distributed in a random arrangement. It became possible.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006531906A JP4731487B2 (ja) | 2004-08-24 | 2005-08-23 | Corl1遺伝子を標的とした脊髄神経細胞の種類を識別する方法 |
US11/574,115 US20080213757A1 (en) | 2004-08-24 | 2005-08-23 | Methods of Distinguishing Types of Spinal Neurons Using Corl1 Gene as an Indicator |
EP05780878A EP1788094A4 (en) | 2004-08-24 | 2005-08-23 | METHOD OF DISTINCTING THE BACKMARK NEURONENTYPE WITH THE CORL1 GENE AS A TARGET |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004243588 | 2004-08-24 | ||
JP2004-243588 | 2004-08-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006022243A1 true WO2006022243A1 (ja) | 2006-03-02 |
Family
ID=35967455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/015245 WO2006022243A1 (ja) | 2004-08-24 | 2005-08-23 | Corl1遺伝子を標的とした脊髄神経細胞の種類を識別する方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20080213757A1 (ja) |
EP (1) | EP1788094A4 (ja) |
JP (1) | JP4731487B2 (ja) |
WO (1) | WO2006022243A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008096817A1 (ja) | 2007-02-09 | 2008-08-14 | Eisai R & D Management Co., Ltd. | Gabaニューロン前駆細胞マーカー65b13 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090203046A1 (en) * | 2005-02-02 | 2009-08-13 | Eisai R& D Management Co., Ltd. | Methods for identifying purkinje cells using the corl2 gene as a target |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6284194A (en) * | 1993-03-12 | 1994-09-26 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5) |
US20090203046A1 (en) * | 2005-02-02 | 2009-08-13 | Eisai R& D Management Co., Ltd. | Methods for identifying purkinje cells using the corl2 gene as a target |
-
2005
- 2005-08-23 EP EP05780878A patent/EP1788094A4/en not_active Withdrawn
- 2005-08-23 WO PCT/JP2005/015245 patent/WO2006022243A1/ja active Application Filing
- 2005-08-23 US US11/574,115 patent/US20080213757A1/en not_active Abandoned
- 2005-08-23 JP JP2006531906A patent/JP4731487B2/ja not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
CASPARY T ET AL: "Patterning cell types in the dorsal spinal cord: what the mouse mutants say.", NAT REV NEUROSCI., vol. 4, no. 4, April 2003 (2003-04-01), pages 290 - 297, XP002992939 * |
HELMS AW ET AL: "Specification of dorsal spinal cord interneurons.", CURR OPIN NEUROBIOL., vol. 13, no. 1, February 2003 (2003-02-01), pages 42 - 49, XP002992940 * |
MIZUHARA E ET AL: "Corl1, a novel neuronal lineage-specific transcriptional corepressor for the homeodomain transcription factor Lbx1.", J BIOL CHEM., vol. 280, no. 5, 4 November 2004 (2004-11-04), pages 3645 - 3655, XP002992938 * |
MULLER T ET AL: "The homeodomain factor lbx1 distinguishes two major programs of neuronal differentiation in the dorsal spinal cord.", NEURON., vol. 34, no. 4, 16 May 2002 (2002-05-16), pages 551 - 562, XP002992941 * |
See also references of EP1788094A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008096817A1 (ja) | 2007-02-09 | 2008-08-14 | Eisai R & D Management Co., Ltd. | Gabaニューロン前駆細胞マーカー65b13 |
US8609405B2 (en) | 2007-02-09 | 2013-12-17 | Eisai R&D Management Co., Ltd. | GABA neuron progenitor cell marker 65B13 |
EP3246407A1 (en) | 2007-02-09 | 2017-11-22 | Eisai R&D Management Co., Ltd. | Gaba neuron progenitor cell marker 65b13 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006022243A1 (ja) | 2008-05-08 |
US20080213757A1 (en) | 2008-09-04 |
EP1788094A1 (en) | 2007-05-23 |
EP1788094A4 (en) | 2009-05-13 |
JP4731487B2 (ja) | 2011-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8580523B2 (en) | Specific marker Lmx1a on dopaminergic neurons | |
US9994816B2 (en) | Lrp4/corin dopamine-producing neuron precursor cell marker | |
JP4118877B2 (ja) | 分裂停止後のドーパミン産生ニューロン前駆細胞に特異的に発現している遺伝子 | |
US8232052B2 (en) | Methods of selecting a dopaminergic neuron proliferative progenitor cells using Lrp4/Corin markers | |
US8609405B2 (en) | GABA neuron progenitor cell marker 65B13 | |
JP4731487B2 (ja) | Corl1遺伝子を標的とした脊髄神経細胞の種類を識別する方法 | |
JP2007306919A (ja) | Lrp4/Corinドーパミン産生ニューロン前駆細胞マーカー | |
JP4085117B2 (ja) | 分裂停止後のドーパミン産生ニューロン前駆細胞に特異的に発現している遺伝子 | |
JP2007185189A (ja) | Lrp4/Corinドーパミン産生ニューロン前駆細胞マーカー |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006531906 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005780878 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005780878 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11574115 Country of ref document: US |